• Aumkhae Sookprasert, Nutjaree Pratheepawanit Johns, Anakapong Phunmanee, Parichart Pongthai, Areewan Cheawchanwattana, Jeff Johns, Julraht Konsil, Preeyaporn Plaimee, Supatra Porasuphatana, and Suthiphan Jitpimolmard.
• Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
• Anticancer Res. 2014 Dec 1; 34 (12): 7327-37.

BackgroundThe MIRCIT trial was a randomized, double-blind, placebo-controlled study of advanced Non-small cell lung cancer (NSCLC).Patients And MethodsPatients were randomized to receive 10 mg or 20 mg of melatonin or placebo. Assessment of health-related quality of life (HRQoL) was completed at baseline, and at 2, 3 and 7 months. Survival and adverse events were collected. DNA damage marker 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) was measured during the first three months of chemotherapy.ResultsPatients in the melatonin-treated group had better adjusted HRQoL scores, with a slightly significantly better score (2.69 points, 95% confidence interval (CI)=0.01-5.38, p=0.049) being found in social well-being. Median survival was 7.3 months (95% CI=3.42-11.14) without significant difference. A great amont of DNA damage marker was observed in the placebo-treated group, and this was associated with lower survival (r(2)=-0.656, p=0.02), implying the protective effect of melatonin in healthy cells.ConclusionMelatonin in combination with chemotherapy did not affect survival and adverse events of advanced patients with NSCLC, but there was a trend for better HRQoL.Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

36 keywords...

hide…